semaglutide

Surgery beat GLP-1 drugs on heart outcomes in a 932,000-patient review

by
Surgery beat GLP-1 drugs on heart outcomes in a 932,000-patient review

A network meta-analysis published in Endocrinology, Diabetes & Metabolism pooled 43 studies covering 932,380 patients and compared bariatric surgery against GLP-1 receptor agonists on hard cardiovascular outcomes. Surgery was associated with reductions in major adverse cardiovascular events, heart failure and myocardial infarction. The drugs were associated with a reduction in major adverse cardiovascular events but … Read more

Reflux is reported two to five times more often on GLP-1 drugs, in three countries

by
Peptide Review Desk news graphic: reflux reported two to five times more often on GLP-1 drugs in three countries

A pharmacovigilance study published online in Gut and Liver on 2 September pooled the national adverse-event databases of the United States, Japan and Canada and found gastroesophageal reflux disease reported roughly two to five times more often for GLP-1 drugs than for a comparator diabetes drug class. The signal held in all three countries. It … Read more

GLP-1 prescribing to children aged 8 to 11 is up sharply and still rare

by
Peptide Review Desk news graphic: GLP-1 prescribing to children aged 8 to 11 is up sharply and still rare

A research brief published in Pediatrics on 4 September finds that GLP-1 prescribing to children aged 8 to 11 with obesity rose steeply between 2019 and 2026 while remaining uncommon: across 3,520,531 children in the dataset, 0.6% received a prescription. Every one of those prescriptions was off-label. The three drugs counted are labelled from age … Read more

Higher semaglutide doses tracked with fewer neuropsychiatric events, not more

by
Typographic cover image: headline reading Higher semaglutide doses tracked with fewer neuropsychiatric events, on the Peptide Review Desk navy brand background

A study of 63,215 patients with pre-existing neuropsychiatric conditions, published on 1 September, found semaglutide associated with broadly lower rates of neuropsychiatric events over two years than metformin, SGLT2 inhibitors or DPP-4 inhibitors. Within the semaglutide group, patients who reached higher doses had fewer such events afterwards — the inverse of the dose-toxicity pattern implied … Read more

Semaglutide slowed ageing and extended lifespan in old female mice

by
Typographic cover image: headline reading Semaglutide slowed ageing and extended lifespan in old female mice, on the Peptide Review Desk navy brand background

A study published in Nature on 2 September reports that semaglutide, started late in life, slowed several measures of ageing in mice and extended how long they lived. The comparison arm was calorie restriction — the one intervention that has reliably stretched rodent lifespan for the better part of a century — and semaglutide matched … Read more

Weight comes back at about a kilogram a month after stopping, meta-analysis estimates

by
Weight comes back at about a kilogram a month after stopping, meta-analysis estimates

A meta-analysis published in Endocrinology, Diabetes & Metabolism in September 2026 puts a number on something patients ask about far more often than they are answered: what happens after you stop. Pooling six studies and 1,776 participants, it estimates weight comes back at 1.04 kg per month, that half of everything lost is back within … Read more

Updated review of 38 trials ranks tirzepatide first among available drugs

by
Updated review of 38 trials ranks tirzepatide first among available drugs

An updated systematic review published in Annals of Internal Medicine on 1 September 2026 pooled 38 randomised trials covering 25,816 adults who had overweight or obesity but not diabetes. It is the cleanest single answer yet to the question most readers arrive with: how much weight does each of these drugs actually take off, above … Read more